hidradenitis
Calculate clinical scores for hidradenitis suppurativa (HS), a dermatologic disease. The scores are typically used for evaluation of efficacy in clinical trials. The scores are not commonly used in clinical practice. The specific scores implemented are Hidradenitis Suppurativa Clinical Response (HiSCR) (Kimball, et al. (2015) <doi:10.1111/jdv.13216>), Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R) (Goldfarb, et al. (2020) <doi:10.1111/bjd.19565>), hidradenitis suppurativa Physician Global Assessment (HS PGA) (Marzano, et al. (2020) <doi:10.1111/jdv.16328>), and the International Hidradenitis Suppurativa Severity Score System (IHS4) (Zouboulis, et al. (2017) <doi:10.1111/bjd.15748>).
- Creation of a severity index for hidradenitis suppurativa that includes a validated quality‐of‐life measure: the HIDRAscore
- Development and validation of the International Hidradenitis Suppurativa Severity Score System ( IHS 4), a novel dynamic scoring system to assess HS severity
- Hidradenitis Suppurativa Area and Severity Index Revised (HASI‐R): psychometric property assessment*
- HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study
This page was built for software: hidradenitis
